- Home
- CEV vs EQ Comparison
CEV vs EQ Comparison
Compare CEV & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEV
- EQ
- Stock Information
- Founded
- CEV 1999
- EQ 2017
- Country
- CEV United States
- EQ United States
- Employees
- CEV N/A
- EQ N/A
- Industry
- CEV Finance/Investors Services
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- CEV Finance
- EQ Health Care
- Exchange
- CEV Nasdaq
- EQ Nasdaq
- Market Cap
- CEV 69.7M
- EQ 67.9M
- IPO Year
- CEV N/A
- EQ 2018
- Fundamental
- Price
- CEV $10.01
- EQ $1.63
- Analyst Decision
- CEV
- EQ Hold
- Analyst Count
- CEV 0
- EQ 2
- Target Price
- CEV N/A
- EQ $1.00
- AVG Volume (30 Days)
- CEV 19.6K
- EQ 2.6M
- Earning Date
- CEV 01-01-0001
- EQ 11-12-2025
- Dividend Yield
- CEV 4.23%
- EQ N/A
- EPS Growth
- CEV N/A
- EQ N/A
- EPS
- CEV 0.36
- EQ N/A
- Revenue
- CEV N/A
- EQ $16,553,000.00
- Revenue This Year
- CEV N/A
- EQ N/A
- Revenue Next Year
- CEV N/A
- EQ N/A
- P/E Ratio
- CEV $29.36
- EQ N/A
- Revenue Growth
- CEV N/A
- EQ N/A
- 52 Week Low
- CEV $8.83
- EQ $0.27
- 52 Week High
- CEV $10.91
- EQ $2.35
- Technical
- Relative Strength Index (RSI)
- CEV 77.83
- EQ 53.75
- Support Level
- CEV $9.89
- EQ $1.78
- Resistance Level
- CEV $10.01
- EQ $2.02
- Average True Range (ATR)
- CEV 0.07
- EQ 0.28
- MACD
- CEV 0.05
- EQ -0.06
- Stochastic Oscillator
- CEV 88.89
- EQ 15.29
About CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.